Is Ozempic Safe? The 2026 Honest Answer

Ozempic (semaglutide) has been FDA-approved in the US since 2017 and is one of the most-prescribed medications worldwide. Its safety profile is well characterized, with both meaningful benefits and real risks. Here is what current data show.

Last updated May 1, 2026.

The Short Answer

Ozempic is considered safe for most eligible adults under medical supervision. It carries an FDA boxed warning for thyroid C-cell tumors (observed in rodents; no established human link). Cardiovascular outcomes are favorable in patients with T2D (SUSTAIN-6). Most patients experience GI side effects that resolve within weeks. People with specific contraindications — listed below — should not take it.

FDA Boxed Warning

The FDA boxed warning on Ozempic — and all GLP-1 receptor agonists — concerns medullary thyroid C-cell tumors observed in rodent studies. The label specifies:

• Contraindicated in personal or family history of medullary thyroid carcinoma (MTC)
• Contraindicated in Multiple Endocrine Neoplasia type 2 (MEN-2)
• Patient counseling on thyroid tumor symptoms (neck mass, dysphagia, dyspnea, hoarseness)

Extensive post-marketing surveillance has not established a clear causal link in humans, but the boxed warning remains. Reasonable interpretation: if you have MTC or MEN-2 history, do not take Ozempic; otherwise the absolute risk appears low.

Cardiovascular Safety: SUSTAIN-6 and Others

The SUSTAIN-6 trial randomized 3,297 patients with T2D and high cardiovascular risk to semaglutide or placebo. Semaglutide significantly reduced major adverse cardiovascular events (MACE) — primarily nonfatal stroke. The cardiovascular safety profile is considered favorable.

The SELECT trial extended this finding to patients with obesity and established cardiovascular disease (without diabetes), supporting Wegovy's expanded indication for cardiovascular risk reduction.

Common Adverse Events from Trials

From the SUSTAIN program and post-marketing surveillance:

• Nausea: 15–20% of patients
• Diarrhea: 8–9%
• Vomiting: 5–9%
• Constipation: 5%
• Abdominal pain: 5–7%
• Decreased appetite: common
• Injection-site reactions: usually mild

Most are dose-dependent and improve in weeks.

Serious Adverse Events: Real Numbers

• Pancreatitis: ~0.1–0.4% in trials. Low absolute risk but real.
• Gallbladder events: 1–2% above placebo, largely attributable to rapid weight loss.
• Severe hypoglycemia: Low with semaglutide alone; higher when combined with insulin or sulfonylureas.
• Acute kidney injury: Usually secondary to severe vomiting/diarrhea and dehydration.
• Allergic reactions: Rare anaphylaxis and angioedema reported in post-marketing.
• Diabetic retinopathy worsening: Transient, in patients with pre-existing retinopathy and rapid HbA1c improvement.

Who Should Not Take Ozempic

• Personal or family history of medullary thyroid carcinoma
• MEN-2
• History of pancreatitis
• Severe gastroparesis or significant GI motility disorder
• Pregnancy or planning pregnancy within 2 months
• Type 1 diabetes (not approved; not appropriate)
• Severe diabetic retinopathy without ophthalmologic evaluation
• Known hypersensitivity to semaglutide

Drug Interactions

• Insulin and sulfonylureas: Significantly increased hypoglycemia risk; dose adjustments needed.
• Oral medications: Slowed gastric emptying may delay absorption. Most clinically significant for narrow-therapeutic-index drugs (e.g., warfarin, thyroid hormone, certain anti-seizure drugs).
• Oral contraceptives: No specific reduction in effectiveness, but consider backup during severe vomiting episodes.

Long-Term Use Considerations

Patients who continue Ozempic long-term generally maintain HbA1c control and weight loss. Stopping leads to gradual loss of effect over weeks to months. There is no established safe upper limit on duration; ongoing monitoring is standard practice.

Special Populations

• Older adults (65+): Generally well-tolerated. Watch for dehydration risk and falls if rapid weight loss.
• Patients with kidney disease: No specific dose adjustment required. Caution with severe vomiting/diarrhea.
• Patients with liver disease: Use with caution in severe hepatic impairment.
• Pediatric patients: Ozempic itself is not approved in children. Wegovy is approved for ages 12+.

Counterfeit Concerns

FDA has issued warnings about counterfeit semaglutide products. These have included unlabeled or mislabeled pens, products sold without prescription, and "research only" peptides. Always obtain Ozempic from a US-licensed pharmacy with a valid prescription.

Related Reading

• Is Semaglutide Safe?
• Full Side Effects Guide
• All About Semaglutide
• How to Get Online

Sources

• Ozempic FDA prescribing information.
• Marso et al. SUSTAIN-6. N Engl J Med 2016;375:1834-1844.
• Lincoff et al. SELECT trial. N Engl J Med 2023.
• FDA MedWatch adverse event reports.